REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
19/01/2026
Voltar para busca
Dado oficial do USPTO
EVERZOM
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
27
Atualização mais recente
20/01/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
42, 44
Data de depósito
04/03/2020
Data de registro
19/01/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
19/01/2021
Última transação
20/01/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
FR
Examinador
TULLY, MATTHEW
Unidade examinadora
L50
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
EVERZOM
Representantes
Arnaud Rainfray O'Brien Barristers and Sollicitors
Classificação técnica
Classes Nice
Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
Medical research and pharmacological research services; analysis of human tissues for medical research purposes; pharmaceutical drug development servicesdevelopment of pharmaceutical preparations and medicines from extracellular vesicles; conducting clinical trials for others; provision of information in connection with medical and scientific research in the field of pharmaceutical products and clinical trials; medical research and laboratory services in the field of human tissuetissue engineering; medical research servicesclinical research in the field of biotherapy; conducting clinical trials for otherscarrying out clinical trials for pharmaceutical products; testing on pharmaceutical products; quality control for othersquality evaluation of pharmaceutical products; research and development in the field of pharmaceuticals and biotechnology; medical research servicesbiologicalclinical and medical research services in the field of biotherapy; scientific research for medical purposes in the field of biotherapy; scientific research in the field of extracellular vesiclesscientific research in the field of analysisisolation and production of extracellular vesicles; laboratory research services concerning pharmaceutical products; stem cell research; scientific research and development in the field of microorganisms and cells; scientific research and development in the field of extracellular vesicles; scientific research services with respect to the isolation and cultivation of human cells and tissues
Classe 44
Medical servicesregenerative medicine services using extracellular vesicles; stem cell therapy servicestherapy services based on stem cells; biotherapy serviceshealth care therapy services for treating cancercardiovascular diseasesacute kidney injurybrain injuryliver injuryosteoarthrisisbone regenerationlung injurycutaneous wound healingfistulastenosisradio induced fibrosisautoimmune diseaseslysosomal storage disordersdegenerative diseasesusing extracellular vesicles; biotherapy servicesmedical services relating to the collectiontreatment and processing of human cells
Publicações
Histórico de despachos e eventos da marca no USPTO.
27 publicações encontradas
NREP
NEW REPRESENTATIVE AT IB RECEIVED
24/12/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
16/05/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
23/04/2021
FIMP
FINAL DISPOSITION PROCESSED
23/04/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
19/04/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
19/01/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/11/2020
PUBO
PUBLISHED FOR OPPOSITION
03/11/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
14/10/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
28/09/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
28/09/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
28/09/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
28/09/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
28/09/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/09/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/09/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/09/2020
RFNT
REFUSAL PROCESSED BY IB
18/07/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/07/2020
RFRR
REFUSAL PROCESSED BY MPU
30/06/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
31/05/2020
CNRT
NON-FINAL ACTION WRITTEN
30/05/2020
DOCK
ASSIGNED TO EXAMINER
21/05/2020
MAFR
APPLICATION FILING RECEIPT MAILED
05/05/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/05/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
30/04/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace EVERZOM ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.